New Be Stronger Than Your Migraine Campaign to Help Sufferers Overcome Barriers to Finding Migraine Pain Relief

65% of Migraine Patients Surveyed Say They Are Dissatisfied With Current

Treatment



Life Coach Rhonda Britten Joins Pfizer to Introduce Motivational Tools for

Patients



Jun 29, 2005, 01:00 ET from Pfizer Inc

    NEW YORK, June 29 /PRNewswire-FirstCall/ -- Pfizer Inc introduced today a
 new education campaign, Be Stronger Than Your Migraine, to help migraine
 sufferers overcome barriers that can prevent them from seeking effective pain
 relief.  About 28 million people suffer from the severe, throbbing pain of
 migraine, which can last from hours to days, keeping sufferers from family,
 work and daily life.
     Yet, two-thirds of patients surveyed say they are less than satisfied with
 their current treatment. Sufferers may often feel discouraged and unmotivated
 to discuss the pain and impact with others, even their doctors.
     "The impact of migraine on a person's life can be tremendous," says Rhonda
 Britten, life coach and star of the reality show Starting Over, "and too many
 are accepting pain as a way of life because they have become too frustrated to
 do anything more to help themselves."
     That's why Britten, a migraine sufferer herself, is helping to launch the
 campaign.  Applying problem-solving techniques that she developed through her
 Fearless Living Institute, Britten worked with Pfizer to create exercises
 designed to motivate sufferers to talk with their physician about their
 treatment needs.  Specifically, the tools take patients through a stepwise
 process that helps them to recognize whether migraine continues to impact
 their daily life, identify why they have not taken action to find adequate
 pain relief, and engage in more productive dialogue with their doctor.  They
 are available in a free informational brochure that will empower sufferers to
 break away from the thinking that keeps them from taking action.
     Dr. Marc Husid, founder and director of the Walton Headache Center and
 assistant clinical professor of neurology at the Medical College of Georgia in
 Augusta, agrees that too many patients suffer needlessly from migraine and
 other chronic headache disorders.  "Studies show that more than half of
 migraine sufferers have never been diagnosed, and only 40 percent treat their
 pain with prescription medication," said Dr. Husid.  "Patients must play an
 active role in seeking out and obtaining the care they need and deserve.  They
 also need to feel comfortable talking with their physicians because active
 conversation about treatment options is the only way that the best treatment
 for them can be identified."
     "I always assumed that all treatment would work the same so I didn't go
 back to my doctor to tell her that I wasn't getting the relief I needed," said
 Vanessa Simmons, a 27 year old who has suffered with migraine since high
 school.  "When she first suggested I try Relpax, I didn't expect it would help
 me, but thankfully I was wrong!  My migraine used to last a couple of days but
 now my pain is usually gone in 60 minutes."*
     For some people, Relpax starts to work in as little as 30 minutes and most
 people get relief within two hours.
     Be Stronger than Your Migraine is designed to help sufferers like Vanessa
 overcome their frustration and seek help from a physician.  The new brochure
 is part of a free tool kit called 'Understanding in a Box' that also includes
 tips for family and friends, the children's book Mama Lion's Migraine and
 information about Relpax(R) (eletriptan HBr), Pfizer's migraine medication.
 The kit can be ordered at http://www.migrainerelief.com or by calling
 1-866-519-0300.
 
     About Relpax
     Relpax(R) (eletriptan HBr) is a product in the class of drugs known as
 "triptans."  It has been studied in clinical trials involving more than 9,000
 patients and more than 70,000 migraine attacks and shown to provide relief of
 migraine pain and its associated symptoms of nausea and sensitivity to light
 and sound.  Clinical studies have also shown that more people experienced
 relief with one dose of Relpax than those taking Imitrex(R) (sumatriptan).
     The most common side effects reported in clinical trials with Relpax
 compared with placebo included dizziness (6 percent vs. 3 percent), nausea (5
 percent vs. 5 percent), weakness (5 percent vs. 3 percent), and tiredness (6
 percent vs. 3 percent).  The adverse events seen with Relpax are similar to
 adverse events reported with triptans as a class.
     As with other triptans, it is strongly recommended that Relpax not be
 given to patients in whom unrecognized coronary artery disease (CAD) is
 predicted by the presence of risk factors, unless a clinical evaluation
 provides evidence that the patient is free of underlying cardiovascular
 disease.  Relpax should not be used within at least 72 hours of treatment with
 the following potent CYP3A4 inhibitors: ketoconazole, itraconazole,
 nefazodone, troleandomycin, clarithromycin, ritonavir, and nelfinavir.
     Patient summary of information for Relpax(R) (eletriptan HBr) can be found
 by visiting http://www.stronger.relpax.com or calling 1-866-802-6900.
 
     * Individual results may vary.
 
     Relpax and TAO are registered trademarks of Pfizer Inc.  Imitrex(R) is a
 registered trademark of GlaxoSmithKline.  All other brands are trademarks of
 their respective owners.
 
 

SOURCE Pfizer Inc
    NEW YORK, June 29 /PRNewswire-FirstCall/ -- Pfizer Inc introduced today a
 new education campaign, Be Stronger Than Your Migraine, to help migraine
 sufferers overcome barriers that can prevent them from seeking effective pain
 relief.  About 28 million people suffer from the severe, throbbing pain of
 migraine, which can last from hours to days, keeping sufferers from family,
 work and daily life.
     Yet, two-thirds of patients surveyed say they are less than satisfied with
 their current treatment. Sufferers may often feel discouraged and unmotivated
 to discuss the pain and impact with others, even their doctors.
     "The impact of migraine on a person's life can be tremendous," says Rhonda
 Britten, life coach and star of the reality show Starting Over, "and too many
 are accepting pain as a way of life because they have become too frustrated to
 do anything more to help themselves."
     That's why Britten, a migraine sufferer herself, is helping to launch the
 campaign.  Applying problem-solving techniques that she developed through her
 Fearless Living Institute, Britten worked with Pfizer to create exercises
 designed to motivate sufferers to talk with their physician about their
 treatment needs.  Specifically, the tools take patients through a stepwise
 process that helps them to recognize whether migraine continues to impact
 their daily life, identify why they have not taken action to find adequate
 pain relief, and engage in more productive dialogue with their doctor.  They
 are available in a free informational brochure that will empower sufferers to
 break away from the thinking that keeps them from taking action.
     Dr. Marc Husid, founder and director of the Walton Headache Center and
 assistant clinical professor of neurology at the Medical College of Georgia in
 Augusta, agrees that too many patients suffer needlessly from migraine and
 other chronic headache disorders.  "Studies show that more than half of
 migraine sufferers have never been diagnosed, and only 40 percent treat their
 pain with prescription medication," said Dr. Husid.  "Patients must play an
 active role in seeking out and obtaining the care they need and deserve.  They
 also need to feel comfortable talking with their physicians because active
 conversation about treatment options is the only way that the best treatment
 for them can be identified."
     "I always assumed that all treatment would work the same so I didn't go
 back to my doctor to tell her that I wasn't getting the relief I needed," said
 Vanessa Simmons, a 27 year old who has suffered with migraine since high
 school.  "When she first suggested I try Relpax, I didn't expect it would help
 me, but thankfully I was wrong!  My migraine used to last a couple of days but
 now my pain is usually gone in 60 minutes."*
     For some people, Relpax starts to work in as little as 30 minutes and most
 people get relief within two hours.
     Be Stronger than Your Migraine is designed to help sufferers like Vanessa
 overcome their frustration and seek help from a physician.  The new brochure
 is part of a free tool kit called 'Understanding in a Box' that also includes
 tips for family and friends, the children's book Mama Lion's Migraine and
 information about Relpax(R) (eletriptan HBr), Pfizer's migraine medication.
 The kit can be ordered at http://www.migrainerelief.com or by calling
 1-866-519-0300.
 
     About Relpax
     Relpax(R) (eletriptan HBr) is a product in the class of drugs known as
 "triptans."  It has been studied in clinical trials involving more than 9,000
 patients and more than 70,000 migraine attacks and shown to provide relief of
 migraine pain and its associated symptoms of nausea and sensitivity to light
 and sound.  Clinical studies have also shown that more people experienced
 relief with one dose of Relpax than those taking Imitrex(R) (sumatriptan).
     The most common side effects reported in clinical trials with Relpax
 compared with placebo included dizziness (6 percent vs. 3 percent), nausea (5
 percent vs. 5 percent), weakness (5 percent vs. 3 percent), and tiredness (6
 percent vs. 3 percent).  The adverse events seen with Relpax are similar to
 adverse events reported with triptans as a class.
     As with other triptans, it is strongly recommended that Relpax not be
 given to patients in whom unrecognized coronary artery disease (CAD) is
 predicted by the presence of risk factors, unless a clinical evaluation
 provides evidence that the patient is free of underlying cardiovascular
 disease.  Relpax should not be used within at least 72 hours of treatment with
 the following potent CYP3A4 inhibitors: ketoconazole, itraconazole,
 nefazodone, troleandomycin, clarithromycin, ritonavir, and nelfinavir.
     Patient summary of information for Relpax(R) (eletriptan HBr) can be found
 by visiting http://www.stronger.relpax.com or calling 1-866-802-6900.
 
     * Individual results may vary.
 
     Relpax and TAO are registered trademarks of Pfizer Inc.  Imitrex(R) is a
 registered trademark of GlaxoSmithKline.  All other brands are trademarks of
 their respective owners.
 
 SOURCE  Pfizer Inc